Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
grade F 3.35 -4.01% -0.14
ADAP closed down 4.01 percent on Wednesday, July 17, 2019, on 79 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ADAP trend table...

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.01%
Stochastic Buy Signal Bullish -4.01%
Oversold Stochastic Weakness -4.01%
Doji - Bullish? Reversal -4.29%
Oversold Stochastic Weakness -4.29%
Narrow Range Bar Range Contraction -2.90%
NR7 Range Contraction -2.90%
Oversold Stochastic Weakness -2.90%
Stochastic Reached Oversold Weakness -2.62%

Older signals for ADAP ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatments Virotherapy Cancer Immunotherapy Non Small Cell Lung Cancer Ovarian Cancer Multiple Myeloma Melanoma Oncolytics Biotech Adoptive Cell Transfer Hematological Malignancies Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Immunotherapy Products Esophageal Cancer Breast And Lung Cancer
Is ADAP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.54
52 Week Low 3.2
Average Volume 253,081
200-Day Moving Average 5.3108
50-Day Moving Average 3.705
20-Day Moving Average 3.6665
10-Day Moving Average 3.543
Average True Range 0.2329
ADX 13.55
+DI 14.2568
-DI 17.4928
Chandelier Exit (Long, 3 ATRs ) 3.4413
Chandelier Exit (Short, 3 ATRs ) 4.0287
Upper Bollinger Band 4.0904
Lower Bollinger Band 3.2426
Percent B (%b) 0.13
BandWidth 23.122869
MACD Line -0.0878
MACD Signal Line -0.0555
MACD Histogram -0.0324
Fundamentals Value
Market Cap 313.29 Million
Num Shares 93.5 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -3.38
Price-to-Sales 39.39
Price-to-Book 2.97
PEG Ratio 0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.56
Resistance 3 (R3) 3.58 3.52 3.53
Resistance 2 (R2) 3.52 3.47 3.52 3.51
Resistance 1 (R1) 3.44 3.44 3.41 3.42 3.50
Pivot Point 3.38 3.38 3.37 3.38 3.38
Support 1 (S1) 3.30 3.33 3.27 3.28 3.20
Support 2 (S2) 3.24 3.30 3.24 3.19
Support 3 (S3) 3.16 3.24 3.18
Support 4 (S4) 3.14